Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
c8-glucosylceramide
- Development stage
- Preclinical
- Lead developer
- Erasmus MC
- Modality
- Small Molecules
- Administration
- Intratumoral, Intravenous
01
Overview
c8-glucosylceramide (also known as C8-GluCer or N-octanoyl-glucosylceramide) is a synthetic short-chain sphingolipid and glycosphingolipid analog. It is primarily investigated as a membrane-modulating adjuvant to enhance the intracellular delivery and therapeutic efficacy of chemotherapeutic agents, such as doxorubicin and mitoxantrone. By inserting into the tumor cell plasma membrane, c8-glucosylceramide increases membrane permeability and facilitates the transmembrane traversal of amphiphilic drugs, thereby overcoming barriers to drug uptake and reversing multidrug resistance. Preclinical research, primarily led by institutions like the Netherlands Cancer Institute and Erasmus University Medical Center, has explored its co-formulation within liposomes or as a pretreatment strategy to improve chemotherapy outcomes in solid tumors, including melanoma and breast carcinoma.
- Other names
- C8-GlcCerC-8-GlcCerC 8-GlcCerC8-GluCerC-8-GluCerC 8-GluCerC8-glucosylceramideC-8-glucosylceramideC 8-glucosylceramideD-glucosyl-beta-1,1' N-octanoyl-D-erythro-sphingosineN-octanoyl-D-erythro-sphingosineN-octanoyl-D-glucosylceramideN-octanoyl-glucosylceramide
02
Targets
UGCG (UDP-glucose ceramide glucosyltransferase)
Beyond the preview
Go deeper on c8-glucosylceramide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on c8-glucosylceramide.